CSL. has filed a patent for a method of dispersing agglomerated material in a preparation containing influenza proteins. The method involves subjecting the preparation to sonication. GlobalData’s report on CSL gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on CSL, Personalized cancer vaccines was a key innovation area identified from patents. CSL's grant share as of September 2023 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Method of dispersing agglomerated material in influenza protein preparation
A recently filed patent (Publication Number: US20230310577A1) describes a preparation and vaccine for influenza that has been subjected to sonication to disperse agglomerated material. Sonication is conducted at a rate of 80% amplitude and for a specific time and intensity to disperse at least 50% of agglomerates present in the preparation. The preparation can include influenza proteins, influenza haemagglutinin, or split influenza virions. It is important to note that the preparation should have a level of less than 0.02% of detergent. The sonication process is conducted to transfer at least 90 Joules/mL of energy.
The patent also describes an influenza vaccine that includes a preparation comprising inactivated or split influenza virions that have been subjected to sonication. The sonication is conducted at a rate of 80% amplitude. The vaccine can include at least 3 different influenza strains and can be either a monovalent vaccine or a quadrivalent vaccine. It is emphasized that the vaccine should be substantially free of agglomerated material.
Additionally, the patent describes a preparation comprising influenza proteins that has been subjected to sonication. The sonication process is conducted to transfer at least 90 Joules/mL of energy. The preparation can include inactivated or split influenza virions from at least 3 different influenza strains and can be a monovalent vaccine or a quadrivalent vaccine. Influenza A and influenza B can also be included in the preparation.
Overall, this patent highlights the use of sonication in the preparation and vaccine for influenza. Sonication is used to disperse agglomerated material and transfer a specific amount of energy to ensure the effectiveness of the preparation and vaccine. The patent also emphasizes the inclusion of specific influenza strains and the absence of agglomerated material in the vaccine.
To know more about GlobalData’s detailed insights on CSL, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
